Dermatologic Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Dermatol Ther. 2021 Mar;34(2):e14778. doi: 10.1111/dth.14778. Epub 2021 Feb 10.
Alopecia areata (AA) is an autoimmune T CD8 cell mediated condition clinically characterized by hair loss from single or few small patches to complete hair loss. The management of AA is challenging and all available therapies does not ensure a long-term remission. To assess the safety and efficacy of both systemic and topical brevilin A, a natural compound, in AA patients not responding to other treatments. After obtaining informed consent, we administered off-label brevilin A to 13 adult patients affected by AA, for a period ranging from 6 to 18 months. Medical records for each patient and the severity of alopecia tool (SALT) score before and after brevilin A administration were recorded. The mean SALT score of our patients was 81.03 (SD 34.9) at baseline and 75.8 (SD 37.4) after brevilin A therapy, meaning no statistically significant improvement was observed (P = .2385 Paired t test). However, three multifocal AA (MAA) patients out of four attained an improvement (75%) suggesting that brevilin A may be represent an alternative therapy in this form of AA. Authors conclude that brevilin A could represent in the future a possible effective treatment in MAA forms but further studies are required.
斑秃（AA）是一种自身免疫性 T CD8 细胞介导的疾病，临床上表现为从单个或少数小斑块到完全脱发的脱发。AA 的治疗具有挑战性，所有可用的治疗方法并不能确保长期缓解。评估天然化合物布列维拉 A（brevilin A）全身和局部给药在对其他治疗无反应的 AA 患者中的安全性和疗效。在获得知情同意后，我们对 13 名成人 AA 患者使用了布列维拉 A（brevilin A），治疗时间从 6 到 18 个月不等。记录了每位患者的病历和使用布列维拉 A 前后的脱发严重程度工具（SALT）评分。我们患者的平均 SALT 评分为 81.03（SD 34.9），使用布列维拉 A 治疗后为 75.8（SD 37.4），这意味着没有观察到统计学上的显著改善（P = 0.2385 配对 t 检验）。然而，4 名多灶性 AA（MAA）患者中有 3 名（75%）病情得到改善，这表明布列维拉 A 可能是这种形式 AA 的另一种治疗方法。作者得出结论，布列维拉 A 可能是未来治疗 MAA 形式的有效方法，但需要进一步研究。
